CNS Disorders  >>  Doria (risperidone extended release)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
PRISMA-1, NCT01788774: Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

Completed
1
36
Europe, RoW
Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg
Rovi Pharmaceuticals Laboratories
Schizophrenia, Schizoaffective Disorder
02/14
02/14
NCT03527186: Comparative Bioavailability of Risperidone

Completed
1
81
US
Risperidone ISM® 100 mg
Rovi Pharmaceuticals Laboratories
Schizophrenia
03/19
04/19
NCT05179525: Comparative Bioavailability of Risperidone.

Completed
1
80
US
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Rovi Pharmaceuticals Laboratories
Schizophrenia
09/21
09/21
QUARTZ, NCT06276361: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

Recruiting
1
100
RoW
Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Deltoids
Rovi Pharmaceuticals Laboratories
Schizophrenia
05/26
05/26

Download Options